Introduction
viral infections, RBD, coronavirus disease 2019
CORONAVIRUS DISEASE 2019, ASYMPTOMATIC COVID-19, VIRAL INFECTION, CORONAVIRUS, SEVERE ACUTE RESPIRATORY SYNDROME
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been widely investigatedT cell-mediated immunity is pivotal for the elimination of viral infections. T cells orchestrate and regulate the immune responses, clear the infected cells, augment the presentation of viral antigens, and maintain the high-affinity antibody production by B lymphocytesThe receptor binding domain (RBD) of SARS-CoV-2 spike (S) glycoprotein is the main target for neutralization; hence, it became a common component in many COVID-19 vaccinesUpon completion of a double-blind, randomized, placebo-controlled phase 3 vaccine trial in Turkey which demonstrated considerable efficiency against symptomatic COVID-19